Retension Pharmaceuticals Announces Completion of Series B Financing to Advance Phase 2b Trial for Uncontrolled and Resistant Hypertension and Issuance of a New U.S. Patent Covering its Lead Candidate, RTN-001
FALLS CHURCH, Va.–(BUSINESS WIRE)–Retension Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of hypertension and other serious cardiovascular diseases, today announced the successful closing of its $15 million Series B…